Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Spero Therapeutics Inc (SPRO)
NASDAQ:SPRO
Holding SPRO?
Track your performance easily
SPRO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.01 - $1.89
Previous Close$1.16
Volume391.27K
Average Volume (3M)238.63K
Market Cap
$63.24M
Enterprise Value-$8.41M
Total Cash (Recent Filing)$76.29M
Total Debt (Recent Filing)$4.63M
Price to Earnings (P/E)14.6
Beta1.42
Next Earnings
Mar 13, 2025EPS Estimate
-$0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.08
Shares Outstanding54,518,165
10 Day Avg. Volume297,808
30 Day Avg. Volume238,625
Standard Deviation0.27
R-Squared0.01
Alpha-0.00939
Financial Highlights & Ratios
Price to Book (P/B)1.00
Price to Sales (P/S)0.66
Price to Cash Flow (P/CF)1.20
P/FCF Ratio1.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.08
Enterprise Value/Gross Profit-0.08
Enterprise Value/Ebitda1.55
Forecast
1Y Price Target
$5.00Price Target Upside331.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Spero Therapeutics News
PremiumCompany Announcements
Spero Therapeutics: Strategic Shift and Earnings UpdateBulls Say, Bears Say
Bulls Say
Financial StabilitySpero Therapeutics has sufficient financial resources to fund its operations and capital expenditures into mid-2026, providing a stable financial outlook.
Partnership And Potential EarningsGlaxoSmithKline is slated to pay Spero up to $400M in potential milestone and royalty payments related to tebipenem HBr.
Regulatory Approval ProspectsThe PIVOT-PO confirmatory pivotal trial of tebipenem HBr is expected to provide sufficient data to support FDA approval for complicated urinary tract infections.
Bears Say
Clinical TrialsThe Phase 2a proof-of-concept study of SPR720 did not meet its primary endpoint, leading to the suspension of its development program.
Corporate RestructuringSpero Therapeutics plans a restructuring and reduction in force of approximately 39% to support other developments.
Safety ConcernsDose limiting safety issues emerged in patients on high dose SPR720, leading to suspension of further development.
---
Ownership Overview
8.31% Insiders
4.37% Mutual Funds
12.81% Other Institutional Investors
71.09% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SPRO FAQ
What was Spero Therapeutics Inc’s price range in the past 12 months?
Spero Therapeutics Inc lowest stock price was $1.01 and its highest was $1.89 in the past 12 months.
What is Spero Therapeutics Inc’s market cap?
Currently, no data Available
When is Spero Therapeutics Inc’s upcoming earnings report date?
Spero Therapeutics Inc’s upcoming earnings report date is Mar 13, 2025 which is in 106 days.
How were Spero Therapeutics Inc’s earnings last quarter?
Spero Therapeutics Inc released its earnings results on Nov 14, 2024. The company reported -$0.32 earnings per share for the quarter, missing the consensus estimate of -$0.265 by -$0.055.
Is Spero Therapeutics Inc overvalued?
According to Wall Street analysts Spero Therapeutics Inc’s price is currently Undervalued.
Does Spero Therapeutics Inc pay dividends?
Spero Therapeutics Inc does not currently pay dividends.
What is Spero Therapeutics Inc’s EPS estimate?
Spero Therapeutics Inc’s EPS estimate is -$0.36.
How many shares outstanding does Spero Therapeutics Inc have?
Spero Therapeutics Inc has 54,518,166 shares outstanding.
What happened to Spero Therapeutics Inc’s price movement after its last earnings report?
Spero Therapeutics Inc reported an EPS of -$0.32 in its last earnings report, missing expectations of -$0.265. Following the earnings report the stock price went down -5.6%.
Which hedge fund is a major shareholder of Spero Therapeutics Inc?
Among the largest hedge funds holding Spero Therapeutics Inc’s share is Royce & Associates LLC. It holds Spero Therapeutics Inc’s shares valued at N/A.
---
Spero Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (331.03% Upside)
$5.00 (331.03% Upside)
Hedge Fund Trend
Decreased
By 22.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $67.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.6%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.13%
12-Months-Change
Fundamentals
Return on Equity
5.90%
Trailing 12-Months
Asset Growth
26.20%
Trailing 12-Months
Company Description
Spero Therapeutics Inc
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. Its pipeline product candidates include SPR994, SPR741, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.
---
SPRO Earnings Call
Q2 2024
0:00 / 0:00
---
SPRO Stock 12 Month Forecast
Average Price Target
$5.00
▲(331.03% Upside)
Technical Analysis
Best Analysts Covering SPRO
1 Year
1 Year Success Rate
2/11 ratings generated profit
1 Year Average Return
-10.52%
reiterated a buy rating 24 days ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 18.18% of your transactions generating a profit, with an average return of -10.52% per trade.
---